Affordable Access

The metabolic syndrome in women: implications for therapy.

Authors
  • Rosano, Giuseppe M C
  • Vitale, Cristiana
  • Silvestri, Antonello
  • Fini, Massimo
Type
Published Article
Journal
International journal of clinical practice. Supplement
Publication Date
Mar 01, 2004
Issue
139
Pages
20–25
Identifiers
PMID: 15117109
Source
Medline
License
Unknown

Abstract

It is becoming increasingly clear that hypertension and metabolic risk factors in women are inter-related and often share underlying causes. Menopause acts explicitly as a risk factor by reducing the direct beneficial effect of ovarian hormones upon cardiovascular functions and indirectly by negatively influencing other risk factors for coronary artery disease--i.e. hyperinsulinaemia, blood cholesterol, blood pressure, coagulation etc. Adverse changes in one factor may induce adverse changes in a variety of other risk factors and it is important to consider co-ordinated changes when evaluating these patients rather than attempt to isolate independent factors. Similarly with treatment, the prevalence of metabolic syndrome in postmenopausal hypertensive women has important implications and some antihypertensive drugs may worsen the already altered metabolic profile of these patients while others may be beneficial. Centrally-acting sympatholytic agents, e.g. moxonidine, are therefore important to consider in hypertensive postmenopausal women who experience other symptoms of metabolic syndrome.

Report this publication

Statistics

Seen <100 times